Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of a Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Standard Fluzone® in Healthy Infants and Young Children.

NCT00391391 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00391391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00391391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of a Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Standard Fluzone® in Healthy Infants and Young Children.
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2006
Completion date
October 31, 2007
Enrollment
520 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, myxovirus infection, orthomyxoviridae infection